Back to Search
Start Over
Pathophysiology and therapy of irinotecan-induced delayed-onset diarrhea in patients with advanced colorectal cancer: a prospective assessment.
- Source :
-
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 1998 Aug; Vol. 16 (8), pp. 2745-51. - Publication Year :
- 1998
-
Abstract
- Purpose: Irinotecan (CPT-11), a camptothecin derivative, has shown efficacy against colorectal cancer. Delayed-onset diarrhea is its main limiting toxicity. The aim of this study was to determine the pathophysiology of CPT-11-induced delayed-onset diarrhea and assess the efficacy of combined antidiarrheal medication in a phase II, prospective, successive-cohorts, open study.<br />Patients and Methods: Twenty-eight patients with advanced colorectal cancer refractory to fluorouracil (5-FU) therapy received CPT-11 350 mg/m2 every 3 weeks. The first cohort of 14 consecutive patients explored for the mechanism of diarrhea received acetorphan (a new enkephalinase inhibitor) 100 mg three times daily; the second 14-patient cohort received, in addition to acetorphan, loperamide 4 mg three times daily. Before treatment, and if late diarrhea occurred, patients underwent colon mucosal biopsies for CPT-11 and topoisomerase I levels; intestinal transit time; fecalogram; fat and protein excretion; alpha1-antitrypsin clearance; D-xylose test; blood levels for vasoactive intestinal polypeptide, glucagon, gastrin, somatostatin, prostaglandin E2, and carboxylesterase; CPT-11/SN-38 and SN-38 glucuronide pharmacokinetics; and stool cultures.<br />Results: Delayed-onset diarrhea occurred during the first three treatment cycles in 23 patients (82%). Electrolyte fecal measurements showed a negative or small osmotic gap in nine of nine patients and an increased alpha1-antitrypsin clearance in six of six patients. There were no modifications in stool cultures or hormonal dysfunction. Four of 11 patients (36%) with delayed-onset diarrhea in the first cohort responded to acetorphan, whereas nine of 10 patients (90%) responded to the combination of acetorphan and loperamide (P < .02).<br />Conclusion: CPT-11-induced delayed-onset diarrhea is caused by a secretory mechanism with an exudative component. Early combined treatment with loperamide and acetorphan seems effective in controlling the diarrheal episodes.
- Subjects :
- Adult
Aged
Antineoplastic Agents, Phytogenic therapeutic use
Camptothecin adverse effects
Camptothecin therapeutic use
Diarrhea drug therapy
Diarrhea physiopathology
Female
Humans
Irinotecan
Loperamide adverse effects
Loperamide therapeutic use
Male
Middle Aged
Prospective Studies
Thiorphan adverse effects
Thiorphan analogs & derivatives
Thiorphan pharmacokinetics
Thiorphan therapeutic use
Antidiarrheals therapeutic use
Antineoplastic Agents, Phytogenic adverse effects
Camptothecin analogs & derivatives
Colorectal Neoplasms drug therapy
Diarrhea chemically induced
Subjects
Details
- Language :
- English
- ISSN :
- 0732-183X
- Volume :
- 16
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 9704727
- Full Text :
- https://doi.org/10.1200/JCO.1998.16.8.2745